Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.381
Abstract: In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront… read more here.
Keywords: newly diagnosed; myeloma; upfront asct; myeloma patients ... See more keywords
Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria
Sign Up to like & getrecommendations! Published in 2021 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-021-01223-y
Abstract: Autologous stem cell transplantation (ASCT1) plays an important role in the management of patients with multiple myeloma (MM) and remains relevant in the era of novel therapeutics [1, 2]. A second autologous transplant, usually after… read more here.
Keywords: autologous transplant; multiple myeloma; peripheral blood; stem ... See more keywords
Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Transplantation"
DOI: 10.1111/petr.14229
Abstract: Medulloblastoma outcomes have improved with craniospinal irradiation and chemotherapy, but such therapy has resulted in poor neurocognitive outcomes for young patients. Chemotherapy‐only regimens with autologous transplant have been implemented with the intention of avoiding radiation.… read more here.
Keywords: toxicity following; autologous transplant; medulloblastoma; tandem ... See more keywords
Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116460
Abstract: Introduction: Post autologous transplant maintenance therapy with lenalidomide for patients with multiple myeloma (MM) is standard of care (McCarthy et al, NEJM, 2012). Vorinostat (SAHA, Zolinza) is a HDAC inhibitor and preclinical data suggested that… read more here.
Keywords: maintenance; autologous transplant; vorinostat; lenalidomide ... See more keywords